What can we learn from IO trials in lung cancer to help us evaluate TIGIT's prospects?
Exploring future IO-IO combination strategies and life cycle management
Where five different targeted therapies are put through their paces
There’s always a parable or two to be had at ASCO and this year was no different, especially in…
The continuous evolution of BCMA CAR-T cell therapy products and how they are doing
A look at early stage CAR-T cell therapies in development
When cell therapies and targeted therapies collide
Five key areas to watch out for at ASCO22
What can we learn from the data on inhibitory checkpoints not named PD(L)1 or TIGIT?
What's the skinny on C4 Therapeutics and other TPD programs at AACR and ASCO?
5 abstracts to watch out for at the ASCO22 meeting in Chicago
Can NK cells help checkpoint blockade work more effectively?